Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This research study involves two investigational drugs, an Activator Ligand (INXN-1001) in
combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001). IL-12 is a
protein that may improve the body's natural response to disease by enhancing the ability of
the immune system to kill tumor cells and may interfere with blood flow to the tumor.
The main purpose of this study is to evaluate the safety and tolerability of tumor injections
of INXN-2001 given in combination with different doses of INXN-1001.